摘要
目的探讨免疫组化指标ER、PR、HER-2在乳腺癌中的表达及其临床意义。方法选取我院收治的210例乳腺癌患者,采用免疫组化法检测ER、PR、HER-2水平。结果 HER-2阳性率为41.0%(86例);腋窝淋巴结转移患者的HER-2阳性率显著高于无腋窝淋巴结转移患者(P<0.05)。PR阳性率为41.9%(88例);腋窝淋巴结转移患者的PR阳性率显著低于无腋窝淋巴结转移患者(P<0.05)。ER阳性率为39.5%(83例);腋窝淋巴结转移患者的ER阳性率显著低于无腋窝淋巴结转移患者(P<0.05)。HER-2表达与ER、PR表达呈负相关(P<0.05)。腋窝淋巴结转移患者的不良预后率显著高于无腋窝淋巴结转移患者(P<0.05);HER-2阳性患者的不良预后率显著高于HER-2阴性患者(P<0.05)。结论 ER、PR、HER-2表达水平与乳腺癌的发生发展密切相关,可用于评估疾病预后,指导临床选择用药。
Objective To explore the expressions of immunohistochemical indicators of ER, PR and HER-2 in breast cancer and its clinical significance. Methods 210 cases of patients with breast cancer admitted to our hospital were selected, and the ER, PR and HER-2 levels were detected by immunohistochemistry. Results The HER-2 positive rate was 41.0% （86 cases）. The HER-2 positive rate in patients with axillary lymph node metastasis was significantly higher than that in patients without axillary lymph node metastasis （P〈0.05）. The PR positive rate was 41.9% （88 cases）. The PR positive rate in patients with axillary lymph node metastasis was significantly lower than that in patients without axillary lymph node metastasis （P〈O.05）. The ER positive rate was 39.5% （83 cases）. The positive rate of ER in patients with axillary lymph node metastasis was significantly lower than that in patients without axillary lymph node metastasis （P 〈0.05）. The HER-2 expression was negatively correlated with ER and PR expressions （P〈0.05）. The poor prognosis rate of patients with axiUary lymph node metastasis was significantly higher than that in patients without axillary lymph node metastasis （P〈0,05）, The poor prognosis rate of HER-2 positive patients was significantly higher than that of HER-2 negative patients （P〈0.05）. Conclusions ER, PR and HER-2 expression levels is closely related to the occurrence and development of breast cancer, which can be used to evaluate the prognosis of desease and guide the clinical selection of medicines.
出处
《临床医学工程》
2017年第9期1247-1248,共2页
Clinical Medicine & Engineering
